NCT05013567Unknown3 期
Randomized, Double-Blind, Parallel, Phase III Superiority Clinical Trial to Evaluate the Efficacy and Safety of Ibuprofen Gel Compared With Placebo in the Treatment of Acute Musculoskeletal Pain
Brainfarma Industria Química e Farmacêutica S/A0 个研究点目标入组 300 人开始时间: 2022年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 300
- 主要终点
- Superiority of ibuprofen gel over placebo in the treatment of acute musculoskeletal pain.
研究概览
简要总结
Phase III clinical trial, multicentre of superiority, randomized, double-blind, parallel groups, placebo-controlled and use of ibuprofen gel in the treatment of acute pain.
详细描述
This study is designed for the relief of acute musculoskeletal pain, characterized by pain in muscles, ligaments, tendons, and nerves.
It is performed in participants of both sexes, over 18 years of age, who have pain of moderate intensity as a result of ankle sprains, upper limb contusions, thigh muscle strains, or torticollis.
The rationale for studying the topical use of ibuprofen is the possibility of an alternative treatment for musculoskeletal pain, avoiding systemic adverse events caused by oral administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have signed the informed consent form;
- •Participants of both genders aged ≥ 18 years;
- •Present acute musculoskeletal pain as a result of: ankle sprains, upper limb contusions, thigh muscle sprains, or torticollis;
- •Present pain of moderate intensity by VAS scale (3 ≤ VAS ≤ 7);
- •Pain onset time is less than 36 hours;
- •Present intact skin at the trauma site;
- •Participants of both sexes with the potential to become pregnant must be truly abstinent or use a highly effective method of contraception throughout the period of 30 days before the administration of the drug until 30 days after the end of treatment;
- •Agree to safety laboratory tests: pregnancy test, complete blood count, and biochemical profile;
- •Be able to understand the nature and purpose of the trial, including the risks and adverse events.
排除标准
- •Participants under the age of 18;
- •Participants with musculoskeletal pain as a result of fractures or dislocations;
- •Participants with mild pain (VAS < 3) at the time of selection;
- •Participants with severe pain (VAS > 7) at the time of selection;
- •Participants with pain onset time greater than 36 hours;
- •Participants with a history of chronic pain and acute pain spikes;
- •Participants with loss of skin integrity at the trauma site;
- •Have a known hypersensitivity reaction to the trial medication or chemically related compounds;
- •Have a prior history of the following comorbidities: asthma or other allergic conditions, uncontrolled heart failure, chronic kidney disease, chronic liver disease, active peptic ulcer disease, or gastrointestinal bleeding;
- •Suspect for COVID-19 according to the criteria defined by the World Health Organization;
- •Regular use of analgesics, non-steroidal analgesics or anticoagulants;
- •Use of oral or topical corticoids in the injured area;
- •Being on medications that have relevant interactions with the trial drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, lithium, methotrexate, acetylsalicylic acid, corticosteroids, oral hypoglycemic agents, beta blockers, angiotensin-converting enzyme inhibitors, antihypertensive agents, and diuretics such as furosemide or thiazide;
- •Have had oral or topical analgesic treatment, including use of non-steroidal analgesics, within 72 hours prior to the screening visit;
- •Participants using traditional Chinese or Japanese therapy (acupuncture);
- •Abusive use of alcoholic beverages;
- •Women who are pregnant, breastfeeding, planning to become pregnant, or who test positive for pregnancy during the trial period;
- •Have participated in a clinical trial within the last 12 months;
- •Have any condition that would preclude participation in the trial in the physician's judgment.
研究组 & 干预措施
Ibuprofen gel 5%
Experimental
干预措施: Ibuprofen gel (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Superiority of ibuprofen gel over placebo in the treatment of acute musculoskeletal pain.
时间窗: 5 days of treatment
The primary endpoint of the study is the proportion of participants achieving at least 50% pain reduction on day 5 of treatment by assessing pain intensity using the Visual Analog Scale (VAS), compared to baseline VAS. (Scale = 0 to 10; 0 = mild pain and 10 = severe pain)
次要结局
- Obtain the overall efficacy evaluation, performed by the investigator at the end of the treatment.(Through study completion, an average of 7 days)
- Number of participants using rescue medication.(Through study completion, an average of 7 days)
- Obtain the overall assessment of effectiveness, performed by the participant at the end of the treatment.(Through study completion, an average of 7 days)
- Time to use of rescue medication.(Through study completion, an average of 7 days)
- Pain relief with study medication on days 3, 5, and 7.(3, 5 and 7 days of treatment)
- Interference of pain on physical activity on days 3, 5 and 7(3, 5 and 7 days of treatment)
- Time needed for pain improvement.(Through study completion, an average of 7 days)
研究者
相似试验
Unknown
3 期
Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute BronchitisAcute BronchitisNCT04260555Daewon Pharmaceutical Co., Ltd.204
已完成
3 期
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With HypertensionEssential HypertensionNCT06671392Daewoong Pharmaceutical Co. LTD.198
已完成
3 期
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic ArthritisArthritis, PsoriaticNCT01087788UCB BIOSCIENCES GmbH409
已完成
3 期
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's DiseaseCrohn's DiseaseNCT02038920Takeda157
已完成
3 期
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid TumorsBone MetastasesNCT04812509Mabwell (Shanghai) Bioscience Co., Ltd.708